The European Medicines Agency (EMA) gave initial endorsement to a new approach methodology aimed at early toxicity testing that replaces live animal controls with “virtual counterparts.” The virtual control groups are derived from prior animal-control datasets, assembled through an EU-funded effort with participation from 20 pharma and crop science companies. This endorsement matters because it is framed as the first time EMA has formally endorsed a non-traditional NAM approach for generating data that could later support marketing authorization applications. While the scope is limited, the validation step is a concrete regulatory signal for the broader 3Rs push and for how sponsors may redesign early safety programs. The approach could reduce animal use while potentially standardizing certain control benchmarking steps—though sponsors will still need to demonstrate that the resulting data meet regulatory expectations for comparability and predictive relevance. For biotech teams developing novel modalities or entering first-in-human programs, the EMA’s move adds another potential pathway to modernize preclinical safety strategies in Europe.